Lion Biotechnologies, Inc. (LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TILs) under a Cooperative Research and Development Agreement with the National Cancer Institute (NCI), today announced that Steven A. Rosenberg, MD, PhD, chief of surgery at the NCI, presented positive, new data from a Phase 2 clinical trial of TIL therapy in metastatic melanoma. The updated results were presented on December 7, 2014 in a scientific symposium on adoptive T-cell therapy (ACT) at the American Society of Hematology annual meeting in San Francisco, CA.
MRV Research
Mortality Not Up With Pregnancy-Associated Malignant Melanoma
Cause-specific mortality does not differ significantly for women and girls with malignant melanoma (MM) diagnosed during pregnancy and up to two years postpartum (pregnancy-associated MM [PAMM]) and with non-PAMM, according to a study published in the December issue of the Journal of the American Academy of Dermatology.
Amgen initiates Phase I trial of melanoma drug combination
US-based Amgen has commenced a Phase I trial of talimogene laherparepvec, an investigational oncolytic immunotherapy, for the treatment of patients with regionally or distantly metastatic melanoma.
Lion Biotechnologies Announces Positive New Data From Lead TIL Melanoma Program at ASH
Lion Biotechnologies, Inc., a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TILs) under a Cooperative Research and Development Agreement with the National Cancer Institute (NCI), today announced that Steven A. Rosenberg, MD, PhD, chief of surgery at the NCI, presented positive, new data from a Phase 2 clinical trial of TIL therapy in metastatic melanoma. The updated results were presented on December 7, 2014 in a scientific symposium on adoptive T-cell therapy (ACT) at the American Society of Hematology annual meeting in San Francisco, CA.